ORGO
Organogenesis Holdings Inc
1.40$
-2.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.2% | +10.4% | +18.4% | -11.6% | +10.0% | -31.6% | +16.2% | +49.3% | +49.6% | -83.5% | +17.5% | – | |
| – | +7.7% | +3.3% | +1.7% | -8.2% | +15.9% | -23.6% | +16.5% | +31.2% | +37.7% | -23.6% | -37.9% | – | |
| – | -13.1% | +13.1% | +24.3% | -12.5% | +8.2% | -34.1% | +16.2% | +56.2% | +53.3% | -100.5% | – | – | |
| – | +12.4% | +8.8% | +21.7% | -33.6% | +11.5% | -7.7% | -2.3% | +27.2% | -22.2% | +47.4% | +20.7% | – | |
| – | -25.4% | +51.0% | +5.8% | -6.2% | -2.5% | +3.5% | +1.8% | +8.0% | +25.6% | -34.9% | -17.2% | – | |
| – | -2.1% | +16.4% | +35.0% | -28.5% | +4.0% | -2.6% | +1.0% | +10.3% | +18.7% | -41.7% | +10.8% | – | |
| – | -115.8% | – | – | – | +63.7% | -297.5% | – | – | +201.3% | -199.7% | – | – | |
| – | +13.1% | +2.4% | +20.6% | -24.0% | -87.0% | +1,475.4% | -30.4% | -38.0% | -43.1% | – | – | – | |
| – | -123.5% | – | – | – | +76.1% | -351.5% | – | – | +199.7% | -208.0% | – | – | |
| – | -127.5% | – | – | -360.0% | – | -369.0% | – | – | – | -162.4% | – | – | |
| – | -117.9% | – | – | – | -37.8% | -345.6% | – | – | +102.6% | -228.5% | – | – | |
| – | -21.0% | -98.7% | -6,850.0% | – | +36.9% | -233.2% | – | – | +150.3% | -179.6% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.